对亨廷顿病的新有希望的基于分子的治疗方法的最新进展
Yangfan Cheng1, Sirui Zhang1, Huifang Shang1
1Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Journal of translational internal medicine
|May 23, 2024
概括
亨廷顿病 (HD) 的治疗方法有限. 本综述探讨了针对亨廷丁基因 (HTT) 和突变亨廷丁蛋白 (mHTT) 的新兴分子疗法,以减缓神经退行.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 亨廷顿病 (HD) 是一种遗传性神经退行性疾病,是由亨廷丁基因 (HTT) 中扩大CAG重复引起的.
- 目前的HD治疗主要是治疗症状,缺乏疾病修饰能力.
- 迫切需要有效的治疗策略来改变HD进展的过程.
研究的目的:
- 审查针对亨廷顿病的基于分子的治疗策略的最新进展.
- 突出关于新兴HD治疗方法的有希望的临床前和临床研究.
- 探索针对HD的遗传和蛋白质基础的新方法.
主要方法:
- 审查目前关于亨廷顿病治疗药物的临床前和临床研究.
- 基于分子点的疗法的分类:DNA,RNA和蛋白质.
- 专注于基因编辑工具,RNA干扰,反意义寡核酸,拼接调节器和蛋白质清除剂.
主要成果:
- 多种分子策略在临床前和临床研究中表现有前途.
- 基因向技术 (ZFNs,TALENs,CRISPR/Cas9) 的目的是纠正遗传缺陷.
- 亨廷降低方法 (RNAi,ASOs,拼接调节器) 减少突变亨廷 (mHTT) 的产生.
- 新的方法,如蛋白质溶解向化马体 (PROTACs),旨在清除现有的mHTT蛋白质.
结论:
- 新兴的分子疗法为治疗亨廷顿病提供了新的希望.
- 目前正在进行的临床试验和临床前研究对于评估治疗疗效至关重要.
- 准HTT基因和mHTT蛋白质代表着HD治疗的重要前沿.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K


